Six events that shaped antibody approvals in oncology
A little over twenty-five years ago, the European Medicines Agency (EMA) and the Food and Drug Administration (FDA) approved the chimeric antibody rituximab which fundamentally altered the landscape of anti-cancer drugs. While only a few antibodies were approved in the immediate years that followed...
Zapisane w:
| Główni autorzy: | , |
|---|---|
| Format: | Artigo |
| Język: | Inglês |
| Wydane: |
Frontiers Media S.A.
2025-02-01
|
| Seria: | Frontiers in Immunology |
| Hasła przedmiotowe: | |
| Dostęp online: | https://www.frontiersin.org/articles/10.3389/fimmu.2025.1533796/full |
| Etykiety: |
Nie ma etykietki, Dołącz pierwszą etykiete!
|